Search Results - "Franke, Fabio A."

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2 by ZUKIN, Mauro, BARRIOS, Carlos H, DA ROCHA BALDOTTO, Clarissa Serodio, METON VIEIRA, Fernando, SMALL, Isabele A, FERREIRA, Carlos G, LILENBAUM, Rogerio C, PEREIRA, Jose Rodrigues, DE ALBUQUERQUE RIBEIRO, Ronaldo, DE MENDONCA BEATO, Carlos Augusto, DO NASCIMENTO, Yeni Neron, MURAD, Andre, FRANKE, Fabio A, PRECIVALE, Maristela, DE LIMA ARAUJO, Luiz Henrique

“…To compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced…”
Get full text

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial by Blay, Jean-Yves, Prof, Pápai, Zsuzsanna, MD, Tolcher, Anthony W, Prof, Italiano, Antoine, MD, Cupissol, Didier, MD, López-Pousa, Antonio, MD, Chawla, Sant P, Bompas, Emmanuelle, MD, Babovic, Nada, MD, Penel, Nicolas, MD, Isambert, Nicolas, MD, Staddon, Arthur P, MD, Saâda-Bouzid, Esma, MD, Santoro, Armando, MD, Franke, Fabio A, MD, Cohen, Patrick, MD, Le-Guennec, Solenn, Demetri, George D, Prof

“…Summary Background Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour activity when…”
Get full text

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer by Beer, Tomasz M, Kwon, Eugene D, Drake, Charles G, Fizazi, Karim, Logothetis, Christopher, Gravis, Gwenaelle, Ganju, Vinod, Polikoff, Jonathan, Saad, Fred, Humanski, Piotr, Piulats, Josep M, Gonzalez Mella, Pablo, Ng, Siobhan S, Jaeger, Dirk, Parnis, Francis X, Franke, Fabio A, Puente, Javier, Carvajal, Roman, Sengeløv, Lisa, McHenry, M Brent, Varma, Arvind, van den Eertwegh, Alfonsus J, Gerritsen, Winald

“…Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic…”
Get full text

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial by Smith, Matthew R, Scher, Howard I, Sandhu, Shahneen, Efstathiou, Eleni, Lara, Primo N, Yu, Evan Y, Chi, Kim N, Ståhl, Olof, Olmos, David, Danila, Daniel C, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, Lopez-Gitlitz, Angela, Parnis, Francis, Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Ferguson, Thomas, Luyten, Daisy, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Mermershtain, Wilmosh, Peer, Avivit, Sella, Avishay, Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Choi, Young-Deuk, Gafanov, Rustem A., Kopyltsov, Evgeniy, Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Attard, Gerhardt, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Emamekhoo, Hamid, Pinski, Jacek K.

“…Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through…”
Get full text

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial by Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof

“…Summary Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to…”
Get full text

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors by Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine, Santos, Ricardo, Mahammedi, Hakim, Ng, Siobhan, Danielli, Riccardo, Franke, Fabio A., Sundar, Santhanam, Agarwal, Neeraj, Bergman, André M., Ciuleanu, Tudor E., Korbenfeld, Ernesto, Sengeløv, Lisa, Hansen, Steinbjorn, McHenry, M. Brent, Chen, Allen, Logothetis, Christopher

“…The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate…”
Get full text

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415) by Maluf, Fernando C., Schutz, Fabio A., Cronemberger, Eduardo H., Luz, Murilo de A., Martins, Suelen P.S., Muniz, David Q.B., Bastos, Diogo A., Cárcano, Flavio M., Smaletz, Oren, Soares, Andrey, Peixoto, Fábio A., Gomes, Andrea J., Cruz, Felipe M., Franke, Fabio A., Herchenhorn, Daniel, dos Santos, Telma M., Fabricio, Vanessa de C., Gidekel, Rosemarie, Werutsky, Gustavo, de Jesus, Rafaela G., Souza, Vinicius C., Fay, André P.

“…Androgen deprivation therapy (ADT) combined with apalutamide, abiraterone acetate plus prednisone, enzalutamide, or docetaxel are the standard treatments for…”
Get full text

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) by Janne, Pasi A., Shaw, Alice Tsang, Pereira, Jose Rodrigues, Jeannin, Gaelle, Vansteenkiste, Johan, Barrios, Carlos H., Franke, Fabio A., Grinsted, Lynda, Smith, Paul D., Zazulina, Victoria, Smith, Ian C., Crino, Lucio

“…Abstract only 7503 Background: KRAS mutations are the most common (~20%) oncogenic alteration in NSCLC. There are no effective targeted therapies for this…”
Get full text

Evaluation of Quality of Life in Patients with Metastatic Colorectal Cancer Treated with Capecitabine by Segalla, José G.M, Van Eyll, Brigitte, Honda Federico, Mirian Hatsue, Skare, Nills G, Franke, Fábio A, Perdicaris, Martha R, de Paula Filho, Urias, Gampel, Otávio, Cabral, Sebastião, de Albuquerque Ribeiro, Ronaldo

“…Abstract Purpose This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who…”
Get full text

CA209-9JC: A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic cutaneous squamous cell carcinoma by Munhoz, Rodrigo Ramella, Camargo, Veridiana Pires De, Marta, Guilherme N, Martins, Jade Cury, Nardo, Mirella, Barbosa, Caroline Chaul, de Souza, Carina Echer, Barbosa, Ingrid, Ricci, Herminia, de Mattos, Marcela Rodrigues, Menezes, Thiago, Machado, Guilherme Urano, Bertolli, Eduardo, Barros, Milton Jose, Franke, Fabio A., Feher, Olavo, Castro, Gilberto

“…Abstract only 10044 Background: Cutaneous squamous cell carcinoma (cSCC) is among the most frequent malignancies worldwide, and an increasing incidence has…”
Get full text

CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer by Kelly, Ronan Joseph, Lockhart, Albert C., Jonker, Derek J., Melichar, Bohuslav, Andre, Thierry, Chau, Ian, Clarke, Stephen John, Cleary, James M., Doki, Yuichiro, Franke, Fabio A., Kitagawa, Yuko, Mariette, Christophe, Montenegro, Paola Catherine, Mendez, Guillermo Ariel, Ciprotti, Marika, Moehler, Markus H.

“…Abstract only TPS4131 Background: Expression of the PD-1 ligands PD-L1 and PD-L2 has been reported in ≈ 40% of pts with E/GEJ cancer and is associated with a…”
Get full text

CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer by Moehler, Markus H., Janjigian, Yelena Yuriy, Adenis, Antoine, Aucoin, Jean-Sebastien, Boku, Narikazu, Chau, Ian, Cleary, James M., Feeney, Kynan, Franke, Fabio A., Mendez, Guillermo Ariel, Schenker, Michael, Li, Mingshun, Hitre, Erika, Couture, Felix, Karamouzis, Michalis, Etienne, Pierre-Luc, Ajani, Jaffer A.

“…Abstract only TPS192 Background: Pts with adv G/GEJ cancer have an OS of ≈ 1 y, indicating an unmet medical need for new first-line treatments. Expression of…”
Get full text

CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer by Moehler, Markus H., Janjigian, Yelena Yuriy, Adenis, Antoine, Aucoin, Jean-Sebastien, Boku, Narikazu, Chau, Ian, Cleary, James M., Feeney, Kynan Tadao, Franke, Fabio A., Mendez, Guillermo Ariel, Schenker, Michael, Li, Mingshun, Hitre, Erika, Couture, Felix, Karamouzis, Michalis, Etienne, Pierre-Luc, Ajani, Jaffer A.

“…Abstract only TPS4132 Background: Pts with adv G/GEJ cancer have an OS of ≈ 1 y, indicating an unmet medical need for new first-line treatments (Tx)…”
Get full text

Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy by Chen, Li-Tzong, Siveke, Jens T, Wang-Gillam, Andrea, Hubner, Richard, Pant, Shubham, Dragovich, Tomislav, Chung, Vincent M., Chang, David Z., Ross, Paul J., Cooray, Prasad, Tebbutt, Niall C., Franke, Fabio A., Belanger, Bruce, Dhindsa, Navreet, de Jong, Floris, Mamlouk, Khalid, Von Hoff, Daniel D.

“…Abstract only…”
Get full text

Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1 trial: A phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy by Chen, Li-Tzong, Siveke, Jens T, Wang-Gillam, Andrea, Hubner, Richard, Pant, Shubham, Dragovich, Tomislav, Chung, Vincent M., Chang, David Z., Ross, Paul J., Cooray, Prasad, Tebbutt, Niall C., Franke, Fabio A., Belanger, Bruce, Dhindsa, Navreet, De Jong, Floris, Mamlouk, Khalid, Von Hoff, Daniel D.

“…Abstract only 425 Background: CA19-9 has been shown to correlate with response to therapy and OS in patients with mPAC. NAPOLI-1, a randomized phase 3 study…”
Get full text

A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies by Papai, Zsuzsanna, Tolcher, Anthony W., Italiano, Antoine, Cupissol, Didier, Lopez-Pousa, Antonio, Chawla, Sant P., Bompas, Emmanuelle, Penel, Nicolas, Isambert, Nicolas, Staddon, Arthur P., Thyss, Antoine, Santoro, Armando, Franke, Fabio A., Cohen, Patrick, Le-Guennec, Solenn, Demetri, George D., Blay, Jean-Yves

“…Abstract only 10506 Background: Ombrabulin (AVE8062) is a vascular disrupting agent that damages established tumor vasculature and has demonstrated synergistic…”
Get full text

A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 by Lilenbaum, Rogerio, Zukin, Mauro, Pereira, Jose Rodrigues, Barrios, Carlos H., De Albuquerque Ribeiro, Ronaldo, Beato, Carlos Augusto de Mendonça, Neron do Nascimento, Yeni, Murad, Andre, Franke, Fabio A., Precivale, Maristela, de Lima Araujo, Luiz Henrique, Baldotto, Clarissa Serodio Da Rocha, Vieira, Fernando Meton, Small, Isabele Avila, Ferreira, Carlos G. M.

“…Abstract only 7506 Background: No standard of care exists for patients with advanced NSCLC and PS 2 and clinical practice ranges from supportive care to…”
Get full text